SPORE in Cervical Cancer - Project 4: A Phase I Safety and Immunogenicity Study of an HPV16-Specific Therapeutic Protein, TA-CIN, Administered Intraumorally during

Grant

Date/time Interval

  • September 1, 2019 - August 31, 2020
  • Total Award Amount

  • 73406.00
  • Direct Costs

  • 51846.00
  • Sponsor Award Id

  • Contributor

  • Charles Leath M.D.   Principal Investigator  
  • Donald Buchsbaum Ph.D.   Investigator